TNFRSF17 and Miyoshi myopathy: CD38 and BCMA are excellent therapeutic targets in MM because of their prevalent expression on neoplastic PCs, and multiple types of targeted therapies have been developed, such as MoAbs, ADCs, bispecific antibodies, and CAR-T cells.